REVIVA PHARMACEUTICALS HOLDINGS, INC.
RVPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RVPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RVPH
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing brilaroxazine, its lead product candidate for schizophrenia and other neuropsychiatric disorders, with no approved products and a history of operating losses.
Key risk: Single product dependency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for REVIVA PHARMACEUTICALS HOLDINGS, INC..
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing brilaroxazine, its lead product candidate for schizophrenia and other neuropsychiatric disorders, with no approved products and a history of operating losses.
- Reviva's lead product candidate is brilaroxazine, which is in clinical development for schizophrenia and other indications; the company has no approved commercial products [sec · filed 2026-04-15].
- As of June 30, 2026, Reviva reported cash and cash equivalents of $19.9M, a net loss of $2.4M, shareholders' equity of $8.6M, and total debt of $0.1M [sec].
- The company expects to require substantial additional funding to complete development and commercialization of brilaroxazine, and its existing cash is not sufficient for those purposes [sec_mda · as of 2026-03-30].
- Reviva is pursuing FDA feedback on a strategy to extend brilaroxazine's commercial exclusivity, with feedback expected mid-year 2026 [sec · filed 2026-04-15].
What works
- Reviva is optimistic about receiving FDA alignment on a strategy to extend brilaroxazine's commercial exclusivity, which could strengthen lifecycle management and long-term intellectual property [sec · filed 2026-04-15].
- A longer exclusivity runway could enhance the opportunity to develop brilaroxazine in multiple high-value indications beyond schizophrenia, including bipolar disorder and major depressive disorder [sec · filed 2026-04-15].
What to weigh
- Reviva's business is entirely dependent on the success of brilaroxazine, its only advanced product candidate, which is still under clinical development and may never receive regulatory approval [sec · filed 2026-04-15].
- The company has a history of operating losses, expects to continue incurring significant expenses, and will need to raise additional capital to fund its operations and development plans [sec_mda · as of 2026-03-30].
- Reviva's existing cash and cash equivalents are not sufficient to complete development of its product candidates or prepare for commercialization [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
Reviva's business depends on brilaroxazine, its only advanced product candidate, which is still in clinical development and may not be approved.
“the success of brilaroxazine, its only advanced product candidate, which is still under clinical development, and if brilaroxazine does not receive regulatory approval or is not successfully commercialized, the Company ' s business will be harmed.”
SEC filings · April 15, 2026
Reviva expects to need substantial additional funding to advance its programs.
“We will require substantial additional funding in order to, among other things, further advance the brilaroxazine progra”
SEC filings · December 23, 2025
Reviva is seeking FDA feedback on a strategy to extend brilaroxazine's exclusivity, with feedback expected mid-year 2026.
“The Company is optimistic about receiving FDA alignment on this strategy, with feedback expected mid-year 2026.”
SEC filings · April 15, 2026
As of December 31, 2025, Reviva had cash and cash equivalents of approximately $14.4 million.
“As of December 31, 2025, we had cash and cash equivalents of approximately $14.4 million.”
SEC MD&A · March 30, 2026
Risks & what to watch (4)›
Key risks
- Single product dependency — Reviva's business is entirely dependent on brilaroxazine, which is still in clinical development and may not be approved [sec · filed 2026-04-15].
- Need for additional funding — Existing cash is insufficient to complete development or commercialization; the company will need to raise significant capital [sec_mda · as of 2026-03-30].
- History of operating losses — Reviva has incurred losses since inception and expects to continue incurring significant expenses and losses [sec_mda · as of 2026-03-30].
- Regulatory and manufacturing risks — The FDA may identify deficiencies in manufacturing processes or facilities of third-party manufacturers [sec · filed 2026-04-15].
What to watch
- FDA feedback on brilaroxazine's exclusivity extension strategy, expected mid-year 2026 [sec · filed 2026-04-15].
- Initiation and progress of the planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia [sec_mda · as of 2026-03-30].
- Future capital raises and cash runway updates, as existing cash is insufficient to complete development [sec_mda · as of 2026-03-30].
Sources: SEC filings · SEC MD&A · Generated August 13, 2026 · How we verify sources →
Run REVIVA PHARMACEUTICALS HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REVIVA PHARMACEUTICALS HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
28.7 months
D/E 0.39
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$2.9M
| Holder | Shares | Value |
|---|---|---|
| millennium management llc | 793,948 | $579K |
| highbridge capital management llc | 762,236 | $556K |
| jpmorgan chase & co | 762,236 | $556K |
| armistice capital, llc | 592,079 | $432K |
| susquehanna international group, llp | 527,800 | $385K |
| vanguard capital management llc | 235,136 | $172K |
| geode capital management, llc | 72,992 | $53K |
| renaissance technologies llc | 43,002 | $31K |
| vanguard fiduciary trust co | 31,598 | $23K |
| state street corp | 19,160 | $14K |
Showing top 10 of 35 institutional holders of REVIVA PHARMACEUTICALS HOLDINGS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 11.5%
- Days to cover
- 1.3
- Shares short
- 1,429,477
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RVPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for REVIVA PHARMACEUTICALS HOLDINGS, INC.?
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing brilaroxazine, its lead product candidate for schizophrenia and other neuropsychiatric disorders, with no approved products and a history of operating losses.
Who is the CEO of REVIVA PHARMACEUTICALS HOLDINGS, INC.?
Dr. Laxminarayan Bhat Ph.D. is the chief executive officer of REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).
Where is REVIVA PHARMACEUTICALS HOLDINGS, INC. headquartered?
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) is headquartered in Cupertino, CA, United States.
What therapeutic areas does REVIVA PHARMACEUTICALS HOLDINGS, INC. focus on?
REVIVA PHARMACEUTICALS HOLDINGS, INC. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.